Fulvestrant in the treatment of advanced breast cancer: A systematic review and meta-analysis of randomized controlled trials

Critical Reviews in Oncology/Hematology

Volumn 73, Issue 3, 2010, Pages 220-227

  Valachis, Antonis ^a   Mauri, Davide ^b,c   Polyzos, Nikolaos P ^b   Mavroudis, Dimitris ^a   Georgoulias, Vassilis ^a   Casazza, Giovanni ^d  

^a UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

^b PACMeR: Medical Oncology and Obstetrics and Gynaecology   (Greece)

^c Hospital of Lamia   (Greece)

^d UNIVERSITY OF MILAN   (Italy)

Author keywords

Breast cancer; Estrogen receptor antagonist; Fulvestrant; Therapy

Indexed keywords

ANASTROZOLE; EXEMESTANE; FULVESTRANT; HORMONE INHIBITOR; TAMOXIFEN;

ADVANCED CANCER; ARTHROPATHY; ASTHENIA; BREAST CANCER; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER PATIENT; CANCER SURVIVAL; CLINICAL TRIAL; DRUG EFFICACY; DRUG FATALITY; DRUG INDUCED HEADACHE; DRUG TOLERABILITY; GASTROINTESTINAL SYMPTOM; HOT FLUSH; HUMAN; META ANALYSIS; NAUSEA; OVERALL SURVIVAL; PAIN; REVIEW; SIDE EFFECT; SYSTEMATIC REVIEW; THROMBOEMBOLISM; TREATMENT RESPONSE; VAGINITIS; VASODILATATION; WEIGHT GAIN;

ANTINEOPLASTIC AGENTS, HORMONAL; AROMATASE INHIBITORS; BREAST NEOPLASMS; ESTRADIOL; FEMALE; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TAMOXIFEN;

EID: 74649086996     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2009.03.006     Document Type: Review

References (27)

1. Buzdar A.U. Endocrine therapy in the treatment of metastatic breast cancer. Semin Oncol 28 (2001) 291-304
2. Wickerham L. Tamoxifen-an update on current data and where it can now be used. Breast Cancer Res Treat 75 1 (2002) S7-S12 [discussion S32-S35]
3. Bonneterre J., Thürlimann B., Robertson J.F., et al. Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study. J Clin Oncol 18 22 (2000) 3748-3757
4. Nabholtz J.M., Buzdar A., Pollak M., et al. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group. J Clin Oncol 18 22 (2000) 3758-3767
5. Mouridsen H., Gershanovich M., Sun Y., et al. Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group. J Clin Oncol 21 11 (2003) 2101-2109
6. Mauri D., Pavlidis N., Polyzos N.P., et al. Survival with aromatase inhibitors and inactivators versus standard hormonal therapy in advanced breast cancer: meta-analysis. J Natl Cancer Inst 98 18 (2006) 1285-1291
7. Addo S., Yates R.A., and Laight A. A phase I trial to assess the pharmacology of the new oestrogen receptor antagonist fulvestrant on the endometrium in healthy postmenopausal volunteers. Br J Cancer 87 (2002) 1354-1359
8. Wakeling A.E. The future of new pure antioestrogens in clinical breast cancer. Breast Cancer Res Treat 25 (1993) 1-9
9. Robertson J.F., Nicholson R.I., Bundred N.J., et al. Comparison of the short-term biological effects of 7alpha-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)-nonyl]estra-1,3,5,(10)-triene-3,17beta-diol (Faslodex) versus tamoxifen in postmenopausal women with primary breast cancer. Cancer Res 61 (2001) 6739-6746
10. Egger M., Smith G.D., and Sterne J.A. Uses and abuses of meta-analysis. Clin Med 1 (2001) 478-484
11. Robertson J.F., Osborne C.K., Howell A., et al. Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women: a prospective combined analysis of two multicenter trials. Cancer 98 2 (2003) 229-238
12. Howell A., Pippen J., Elledge R.M., et al. Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma: a prospectively planned combined survival analysis of two multicenter trials. Cancer 104 July (2) (2005) 236-239
13. Mauriac L., Pippen J.E., Quaresma Albano J., Gertler S.Z., and Osborne C.K. Fulvestrant (Faslodex) versus anastrozole for the second-line treatment of advanced breast cancer in subgroups of postmenopausal women with visceral and non-visceral metastases: combined results from two multicentre trials. Eur J Cancer 39 9 (2003) 1228-1233
14. Dodwell D., and Pippen J. Time to response: comparison of fulvestrant and oral endocrine agents. Clin Breast Cancer 7 3 (2006) 244-247
15. Howell A., Robertson J.F., Quaresma Albano J., et al. Fulvestrant, formerly ICI 182, 780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. J Clin Oncol 20 16 (2002) 3396-3403
16. Osborne C.K., Pippen J., Jones S.E., et al. A double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial. J Clin Oncol 20 16 (2002) 3386-3395
17. Chia S., Gradishar W., Mauriac L., et al. Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT. J Clin Oncol 26 April (10) (2008) 1664-1670
18. Howell A., Robertson J.F., Abram P., et al. Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trial. J Clin Oncol 22 9 (2004) 1605-1613
19. Addo S., Yates R.A., and Laight A. A phase I trial to assess the pharmacology of new oestrogen receptor antagonist fulvestrant on the endometrium in healthy postmenopausal volunteers. Br J Cancer 87 (2002) 1354-1359
20. Bergman L., Beelen M.L., Gallee M.P., et al. Risk and prognosis of endometrial cancer after tamoxifen for breast cancer. Comprehensive Cancer Centres' ALERT Group. Assessment of liver and endometrial cancer risk following tamoxifen. Lancet 356 (2000) 881-887
21. Jelovac D., Macedo L., Goloubeva O.G., et al. Additive antitumor effect of aromatase inhibitor letrozole and antioestrogens fulvestrant in a postmenopausal breast cancer model. Cancer Res 65 (2005) 5439-5444
22. Dodwell D., and Vergote I. A comparison of fulvestrant and the third-generation aromatase inhibitors in the second-line treatment of postmenopausal women with advanced breast cancer. Cancer Treat Rev 31 (2005) 274-282
23. Steger G.G., Bartsch R., Wenzel C., et al. Fulvestrant ('Faslodex') in pretreated patients with advanced breast cancer: a single-centre experience. Eur J Cancer 41 (2005) 2655-2661
24. Steger G.G., Gips M., Simon S.D., et al. Fulvestrant ('Faslodex'): clinical experience from the Compassionate Use Programme. Cancer Treat Rev 31 Suppl. 2 (2005) S10-S16
25. Lau J., Ioannidis J.P., and Schmid C.H. Summing up evidence: one answer is not always enough. Lancet 351 (1998) 123-127
26. Stewart L.A., and Tierney J.F. To IPD or not to IPD? Advantages and disadvantages of systematic reviews using individual patient data. Eval Health Prof 25 (2002) 76-97
27. Clarke M., Stewart L., Pignon J.P., and Bijnens L. Individual patient data meta-analysis in cancer. Br J Cancer 77 (1998) 2036-2044